CONATUS PHARMACEUTICALS INC. (NASDAQ:CNAT) Files An 8-K Termination of a Material Definitive AgreementItem 1.02
On December 19, 2016, Conatus Pharmaceuticals Inc. (the “Company”) provided written notice to MLV & Co. LLC (“MLV”) of termination of the parties’ At Market Issuance Sales Agreement dated August 14, 2014 (the “Sales Agreement”). Under the Sales Agreement, the Company could sell from time to time, at its option, up to an aggregate of $50.0 million of shares of its common stock through MLV, as sales agent. The termination will become effective ten days after the Company’s written notice to MLV, or December 29, 2016.
The foregoing description of the Sales Agreement is qualified in its entirety by reference to the complete text of the Sales Agreement, a copy of which was filed as Exhibit 1.2 to the Company’s Registration Statement on Form S-3, filed with the Securities and Exchange Commission on August 14, 2014 (No. 333-198142).
About CONATUS PHARMACEUTICALS INC. (NASDAQ:CNAT)
